OakChart

SpyGlass Pharma Inc

SGPHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

34.97+0.79 (2.31%)
2026-11-12 00:05 CET
Market cap
1,143.25 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-19.86 USD m
Free cash flow, TTM
-16.77 USD m
EPS diluted, TTM
-0.59
P/E
-
Compare

Price

SGP against its 20 and 50-day averages
2050earnings
20.0030.0040.00739K1.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SGPclose 34.9720-day 31.1750-day 28.6034.9752w high52w low

12.4% under the 52-week high of 39.92 on 9 Nov 2026. 52-week low 17.06 on 17 Jun 2026. Last 15 sessions, 49.7% high to low

Volume 0.70× normal · the line is the 50-bar volume average

Profile

SGP
52-week range, 78% of the way up
17.0639.92

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

IndexRUT
Employees65
IPOFeb 06, 2026
ATR, 14d2.21
Rel volume0.70
Short float8.31%
Insider own58.24%
Inst own41.80%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.17B
Enterprise Value937.11M
Income-
Sales-
Book/sh6.95
Cash/sh7.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees65
IPOFeb 06, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.03
P/C4.99
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio25.06
Current Ratio25.06
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-2.81
EPS next Q-0.62
EPS this Y86.10%
EPS next Y-12.63%
EPS next 5Y44.60%
EPS past 3/5Y-69.04% -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q84.99%
Sales Q/Q-
EarningsNov 11 AMC
EPS/Sales Surpr.-14.70% -

Ownership

Insider Own58.24%
Insider Trans0.00%
Inst Own41.80%
Inst Trans2.49%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2012.19%
SMA5022.26%
SMA20040.95%
Trades-

Technical

Shs Outstand33.45M
Shs Float13.97M
Short Float8.31%
Short Ratio10.50
Short Interest1.16M
52W High39.92 -12.40%
52W Low17.06 104.98%
Volatility9.04% 7.00%
ATR (14)2.21
RSI (14)62.91
Beta-
Rel Volume0.70
Avg Volume110.54K
Volume77,573

Performance

Perf Week1.51%
Perf Month46.20%
Perf Quarter38.94%
Perf Half Y46.81%
Perf YTD45.71%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.17
Target Price44.00
Prev Close34.18
Price34.97
Change %2.31%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Aug 14, 2026InitiatedRRaymond JamesOutperform$39+11.5%
Mar 10, 2026InitiatedHH.C. WainwrightBuy$37+5.8%
Mar 03, 2026InitiatedSStifelBuy$42+20.1%
Mar 03, 2026InitiatedLLeerink PartnersOutperform$42+20.1%
Mar 03, 2026InitiatedJJefferiesBuy$62+77.3%
Mar 03, 2026InitiatedCCitigroupBuy$42+20.1%

Peers

Mkt cap
TickerCompanyMkt cap
OCULOcular Therapeutix Inc1.47B
EYPTEyePoint Inc30.74M
OCSOculis Holding AG469.78M
TARSTarsus Pharmaceuticals Inc3.78B
KLRSKalaris Therapeutics Inc41.50M
KODKodiak Sciences Inc6.87B
AURAAura Biosciences Inc792.01M
OTLKOutlook Therapeutics Inc117.10M
ALDXAldeyra Therapeutics Inc39.32M
OKYOOKYO Pharma Limited74.52M

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09 '26Buy16.003,690,00059,040,0005,966,439Feb 11 05:15 PM
Behbahani AliDirectorFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Florence Anthony A. Jr.10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
BASKETT FOREST10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
New Enterprise Associates 17,10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Yang Rick10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Makhzoumi Mohamad10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
SANDELL SCOTT D10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Chang Carmen10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Walker Paul Edward10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Mathers Edward T10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Pardo Geoffrey BDirectorFeb 09 '26Buy16.00312,5005,000,0002,187,513Feb 11 04:09 PM
Khan Bilal ArshadDirectorFeb 09 '26Buy16.00115,0001,840,000251,427Feb 11 04:07 PM
Khan Bilal ArshadDirectorFeb 09 '26Buy16.0020,000320,00025,450Feb 11 04:07 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
BBCVirtus Biotech Clinical Trials ETFAUM: 31.26M

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11--0.623--0.006
2026Q22026-08-06-0.590-0.514-0.000.005
2026Q12026-05-14-0.690-0.503-0.6930.000.005
2025Q42026-03-26-5.720-0.574-0.3760.000.002
2026Q4---0.653--0.006
2027Q1---0.633--0.004
2027Q2---0.652--0.004
2027Q3---0.723--0.003
2027Q4---0.710--0.003
2028Q1---0.920---1
2028Q2---0.990---1
2028Q3---1.060---1
2028Q4---1.130---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-17.980-1.985-0.000.00
2026FY--2.499--0.00
2027FY--2.814--0.00
2028FY--3.057--0.00
2029FY--3.070--18.86
2030FY--2.680--85.58

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-134000.000.000.00
2026Q3S2026-08-073000.000.000.00
2026Q3S2026-08-063000.000.000.00
2026Q3S2026-05-153000.000.000.00
2026Q3S2026-03-273000.000.000.00
2026Q3S2026-03-093000.000.000.00
2026Q3S2026-03-032000.000.000.00
2026Q3S2026-03-021000.000.000.00
2026Q3E2026-10-21600-0.62-0.71-0.52
2026Q3E2026-08-13614-0.62-0.71-0.52
2026Q3E2026-08-07514-0.62-0.71-0.52
2026Q3E2026-08-06501-0.56-0.74-0.50
2026Q3E2026-07-29501-0.56-0.74-0.50
2026Q3E2026-05-28513-0.56-0.74-0.50

Estimate history

EPS, annual-0.417-0.914-1.193
Period202320242025
EPS, quarterly-0.263-3.957-0.26-0.376-0.693-0.594
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26
Sales, annual000
Period202320242025
Sales, quarterly000000
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26
Shares, annual31.91131.91133.42733.446
Period202320242025MRQ
Shares, quarterly31.911-33.43333.42733.43333.446
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue0.000.000.000.00
Cost of Goods Sold Incl. D&A0.340.610.270.12
Gross Profit-0.34-0.61-0.27-0.12
Selling, General and Administrative Excl. Other21.6340.8426.7914.11
Research and Development10.6228.6419.819.88
Other Operating Expense0.000.000.000.00
Operating Income-21.97-41.45-27.06-14.23
Interest Expense0.000.000.000.00
Unusual Expense0.001.533.420.00
Net Income Before Taxes-19.86-39.87-29.16-13.32
Income Taxes0.000.000.000.00
Consolidated Net Income-19.86-39.87-29.16-13.32
Net Income From Continuing Operations-19.86-39.87-29.16-13.32
Net Income-19.86-39.87-29.16-13.32
EPS (Recurring)-0.59-1.16-0.84-0.42
EPS (Basic, Before Extraordinaries)-0.59-1.19-0.91-0.42
EPS (Diluted)-0.59-1.19-0.91-0.42
EBITDA-21.63-40.84-26.79-14.11
Non-Operating Income (Expense)2.103.111.320.91
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense1.682.791.490.87
Shares Outstanding33.4533.4331.9131.91
Market Capitalization1,143.251,143.25--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.340.320.220.140.120.11
Gross Profit-0.34-0.32-0.22-0.14-0.12-0.11
Selling, General and Administrative Excl. Other21.6315.0913.419.167.307.65
Research and Development10.628.247.517.215.955.67
Other Operating Expense0.000.000.000.000.000.00
Operating Income-21.97-15.41-13.63-9.30-7.42-7.75
Interest Expense0.000.000.000.000.000.00
Unusual Expense0.000.00-0.000.001.530.85
Net Income Before Taxes-19.86-13.82-12.56-8.68-8.82-8.40
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-19.86-13.82-12.56-8.68-8.82-8.40
Net Income From Continuing Operations-19.86-13.82-12.56-8.68-8.82-8.40
Net Income-19.86-13.82-12.56-8.68-8.82-8.40
EPS (Recurring)-0.59-0.69-0.38-0.26-3.48-0.24
EPS (Basic, Before Extraordinaries)-0.59-0.69-0.38-0.26-3.96-0.26
EPS (Diluted)-0.59-0.69-0.38-0.26-3.96-0.26
EBITDA-21.63-15.09-13.41-9.16-7.30-7.65
Non-Operating Income (Expense)2.101.591.070.620.130.21
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense1.681.680.920.000.340.41
Shares Outstanding33.4533.4333.4333.43-31.91
Market Capitalization1,143.25866.08781.18---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments107.4416.2740.32
Short Term Receivables0.430.420.12
Inventories0.000.000.00
Other Current Assets0.900.720.18
Total Current Assets108.7717.4140.61
Net Property, Plant & Equipment3.895.460.45
Total Investments and Advances0.000.000.00
Deferred Tax Assets0.460.910.12
Other Assets3.210.450.09
Total Assets116.3324.2341.27
Short Term Debt Incl. Current Port. of LT Debt0.000.440.00
Accounts Payable2.701.980.64
Other Current Liabilities5.895.370.95
Total Current Liabilities8.587.791.59
Long Term Debt1.583.460.00
Provision for Risks Charges0.000.000.00
Deferred Tax Liabilities0.460.910.12
Other Liabilities0.000.000.00
Total Liabilities10.6312.151.71
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value204.5472.5572.55
Common Equity-98.84-60.47-32.99
Total Shareholders Equity105.7012.0739.56
Accumulated Minority Interest0.000.000.00
Total Equity105.7012.0739.56
Total Liabilities & Stockholders Equity116.3324.2341.27
Book Value Per Share-2.96-1.90-1.03
Tangible Book Value Per Share-2.96-1.90-1.03
Full-Time Employees65--
Price to Book Ratio4.92--
Return on Assets-56.73-89.05-
Return on Equity-67.71-112.97-
Return on Invested Capital-37.16-187.83-33.67
Quick Ratio12.672.2325.57
Current Ratio12.672.2325.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-19.86-39.87-29.16-13.32
Depreciation0.340.610.270.12
Other Funds (Non Cash)2.214.115.530.81
Funds from Operations-17.32-35.15-23.37-12.39
Extraordinary Item0.000.000.000.00
Changes in Working Capital2.482.451.340.11
Cash from Operating Activities-14.84-32.70-22.03-12.28
Capital Expenditures-1.93-0.79-1.99-0.22
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments1.00-11.0124.25-20.27
Purchase of Investments-7.00-17.00-20.63-34.04
Sale Or Maturity of Investments8.006.0044.8813.77
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-0.93-11.7922.26-20.49
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.00
Change in Capital Stock0.01124.580.1839.77
Repurchase of Common Pref Stock0.00-1.450.000.00
Sale of Common Pref Stock0.01126.030.1839.77
Proceedsfrom Stock Options2.73125.860.0039.76
Issuance or Reduction of Debt, Net0.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities0.01124.580.1839.77
Net Change in Cash-15.7680.090.427.01
Free Cash Flow-16.77-33.49-24.02-12.49
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Cash & Short Term Investments234.19251.00107.44--16.27
Short Term Receivables0.680.650.43--0.42
Inventories0.000.000.00--0.00
Other Current Assets1.601.710.90--0.72
Total Current Assets236.46253.36108.77--17.41
Net Property, Plant & Equipment6.214.243.89--5.46
Total Investments and Advances0.000.000.00--0.00
Deferred Tax Assets--0.46--0.91
Other Assets0.760.793.21--0.45
Total Assets243.43258.39116.33--24.23
Short Term Debt Incl. Current Port. of LT Debt0.000.000.00--0.44
Accounts Payable4.163.512.70--1.98
Other Current Liabilities5.283.155.89--5.37
Total Current Liabilities9.446.678.58--7.79
Long Term Debt1.631.611.58--3.46
Provision for Risks Charges0.000.000.00--0.00
Deferred Tax Liabilities--0.46--0.91
Other Liabilities0.000.000.00--0.00
Total Liabilities11.078.2710.63--12.15
Non-Equity Reserves0.000.000.00--0.00
Preferred Stock - Carrying Value0.000.00204.54--72.55
Common Equity232.36250.11-98.84---60.47
Total Shareholders Equity232.36250.11105.70--12.07
Accumulated Minority Interest0.000.000.00--0.00
Total Equity232.36250.11105.70--12.07
Total Liabilities & Stockholders Equity243.43258.39116.33--24.23
Book Value Per Share6.957.48-2.96---1.90
Tangible Book Value Per Share6.957.48-2.96---1.90
Full-Time Employees--65---
Price to Book Ratio4.92-8.76-7.90---
Return on Invested Capital-8.49-5.49-11.70---54.10
Quick Ratio25.0638.0012.67--2.23
Current Ratio25.0638.0012.67--2.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Net Income-19.86-13.82--8.68-8.82-
Depreciation0.340.32-0.130.12-
Other Funds (Non Cash)2.211.71-0.691.97-
Funds from Operations-17.32-11.79--7.85-6.73-
Extraordinary Item0.000.00-0.000.00-
Changes in Working Capital2.48-1.75-1.52-1.47-
Cash from Operating Activities-14.84-13.54--6.33-8.20-
Capital Expenditures-1.93-0.68--0.05-0.16-
Net Assets From Acquisitions0.000.00-0.000.00-
Sale of Fixed Assets and Businesses0.000.00-0.000.00-
Purchase or Sale of Investments1.00-0.99-0.000.00-
Purchase of Investments-7.00-4.00-0.000.00-
Sale Or Maturity of Investments8.003.01-0.000.00-
Other Uses0.000.00-0.000.00-
Other Sources0.000.00-0.000.00-
Cash from Investing Activities-0.93-1.67--0.05-0.16-
Cash Dividends Paid0.000.00-0.000.00-
Preferred Dividends (Cash Flow)0.000.00-0.000.00-
Change in Capital Stock0.01157.75-75.6150.10-
Repurchase of Common Pref Stock0.000.00--1.450.00-
Sale of Common Pref Stock0.01157.75-77.0650.10-
Proceedsfrom Stock Options2.73157.70-77.0550.00-
Issuance or Reduction of Debt, Net0.000.00-0.000.00-
Change in Long Term Debt0.000.00-0.000.00-
Issuance of Long Term Debt0.000.00-0.000.00-
Reduction of Long Term Debt0.000.00-0.000.00-
Net Financing Active Other Cash Flow0.000.00-0.000.00-
Other Financing Activities Uses0.000.00-0.000.00-
Cash from Financing Activities0.01157.75-75.6150.10-
Net Change in Cash-15.76142.54-69.2441.73-
Free Cash Flow-16.77-14.22--6.38-8.37-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.31%1.2M14.0M101.55K
2026-10-158.76%1.2M14.0M101.74K
2026-09-308.97%1.3M14.0M112.09K
2026-09-158.80%1.2M14.0M120.52K
2026-08-317.85%1.1M14.0M114.14K
2026-08-148.14%1.1M14.0M112.58K
2026-07-318.17%1.1M14.0M111.08K
2026-07-158.11%1.1M14.0M103.80K
2026-06-309.40%1.3M14.0M96.25K
2026-06-157.25%1.0M14.0M88.14K
2026-05-298.20%1.1M14.0M96.84K
2026-05-156.15%0.9M14.0M102.10K
2026-04-306.10%0.9M14.5M128.40K
2026-04-1517.78%1.0M5.9M145.93K
2026-03-3116.45%1.0M5.9M158.98K
2026-03-139.73%0.6M5.8M152.78K
2026-02-275.48%0.3M5.8M171.75K
2026-02-133.11%0.2M5.8M284.86K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-198-KCurrent report2026-10-19SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-268-KCurrent report2026-03-26SEC
2026-03-098-KCurrent report2026-03-09SEC
2026-02-17SCHEDULE 13GSEC
2026-02-17SCHEDULE 13DSEC
2026-02-13SCHEDULE 13GSEC
2026-02-138-KCurrent report2026-02-12SEC
2026-02-13SCHEDULE 13DSEC
2026-02-13SCHEDULE 13DSEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114/A2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-114Statement of changes in beneficial ownership of securities2026-02-09SEC
2026-02-10SCHEDULE 13DSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-02221.48M1600
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.23.99%
NEA Management Company, LLC22.11%
Sands Capital Alternatives, LLC7.48%
Samsara BioCapital, LLC6.31%
BlackRock, Inc.2.13%
PRICE T ROWE ASSOCIATES INC /MD/2.02%
Vestal Point Capital, LP2.00%
JPMORGAN CHASE & CO1.88%
DEERFIELD MANAGEMENT COMPANY, L.P.1.65%
MILLENNIUM MANAGEMENT LLC1.52%

Funds

Fund% owned
Avantis Emerging Markets Equity ETF8.07%
Xtrackers International Real Estate ETF8.06%
PGIM Global Real Estate Fund7.90%
Avantis Real Estate ETF4.13%
Vert Global Sustainable Real Estate ETF3.70%
BlackRock Advantage International Fund3.55%
Global Real Estate Index Fund2.83%
Franklin International Core Dividend Tilt Index ETF2.79%
Xtrackers MSCI EAFE Hedged Equity ETF2.79%
PGIM Select Real Estate Fund2.59%

OakChart. SGP. Cached 15 minutes.

Some panels did not load: news.